Having just announced a major investment into a new UK Discovery Centre in London that is set to open in 2020, MSD is committed to leverage on the UK’s potential in driving forward early stage discovery. Louise Houson, Managing Director for the UK and Ireland explains the reasons for that investment decision and highlights how working in partnership with all stakeholders will allow the UK to remain a top market for innovations post-Brexit.
MSD globally is committed to being a primary research-intense biopharmaceutical company, and R&D is at the heart of our organization. The intent of the planned Discovery Centre in London is to tap into the European early discovery ecosystem
